medigraphic.com
ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2004, Number 4

<< Back Next >>

Salud Mental 2004; 27 (4)

Estudio comparativo respecto a consideraciones clínicas y psicoterapéuticas en el tratamiento biopsicosocial de la esquizofrenia. Parte II

Valencia CM, Ortega-Soto HA, Rodríguez V MS, Gómez CL

Language: Spanish
References: 70
Page: 35-43
PDF size: 197.35 Kb.


Text Extraction

No abstract


REFERENCES

  1. ASOCIACION PSIQUIATRICA AMERICANA. Manual Diagnóstico y Estadístico de los Trastornos Mentales, DSM IV. Edit Masson, Barcelona, 1994.

  2. ASOCIACION PSIQUIATRICA AMERICANA. Escala de Evaluación de la Actividad Global-EEAG. Eje V, DSM IV. Edit Masson, Barcelona, 1994.

  3. BABIKER IE. Noncompliance in schizophrenia. Psychiatric Dev, 4:329-337, 1986.

  4. BACHRACH LL. Psychosocial rehabilitation and psychiatry in the treatment of schizophrenia-what are the bundaries?. Acta Psychiatr Scan, 407(102):6-10, 2000.

  5. BEBBINGTON PE: The content and context of noncompliance. International Clinical Psychopharmacology, 9 (Supl 5):41-50, 1995

  6. BELLACK AS, MUESER KT: A comprehensive treatment program for schizophrenia and chronic mental illness. Community Mental Health J, 22:175-89, 1993

  7. BENTON MK, SCHOROEDER HE: Social skills training with schizophrenics, meta-analytic evaluation. J Consulting Clin Psychology, 58:741-47, 1990

  8. BREEKE J, LONG J: Community based psychosocial rehabilitation and prospective change in functional, clinical and subjective experience variables in schizophrenia. Schizophrenia Bull, 26:667-680, 2000.

  9. BRENNER HD, RODER V, HODEL B, KIENZLE N, REED D: Integrated Psychological Therapy for Schizophrenic Patients. Hogefre & Huber. Seattle, 1994.

  10. CARPENTER WTJr, KEITH SJ: Integrating treatments in schizophrenia. Psychiatric Clinics North America, 9:153-164, 1986.

  11. CORRIGAN PW,LIBERMAN RP, ENGEL JD: From noncompliance to collaboration in the treatment of schizophrenia. Hosp Community Psychiatry, 41:1203-1211, 1990.

  12. CURSON DA, BARNES TR, BAMBER RW: Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council flufenazine/placebo trial. II The incidence of compliance problems, side effects,, neurotic symptoms and depression. Br J Psychiatry, 146:469-474, 1985.

  13. DAVIS JM, KANE JM, MARDER SR, BRAUZER B, GIERL B y cols.: Dose response of prophylactic antipsychotics. J Clin Psychiatry, 54(3):24-30, 1993.

  14. DIAZ R, MUROW E, ORTEGA H, VALENCIA M, RASCON ML, RAMIREZ I: El manejo integral del paciente esquizofrénico. Un modelo del Instituto Mexicano de Psiquiatría. Salud Mental, 19(4):1-7, 1996.

  15. DIAZ R, RASCON ML, ORTEGA H, MURROW E, VALENCIA M: Evaluación de un programa de rehabilitación del paciente esquizofrénico. Rev Facultad Medicina, 41(2):51- 59, 1998.

  16. DIAZ R, RASCON ML, VALENCIA M, UNIKEL C, MUROW E y cols.: El programa de rehabilitación integral del paciente esquizofrénico del Instituto Mexicano de Psiquiatría. Seguimiento a dos años. Salud Mental, 22(número especial):104-113, 1999.

  17. DIMASCIO A, BERNARDO DL, GREENBLANT DJ: A controlled trial of amantadine in drug-induced extrapiramidal disorders. Arch Gen Psychiatry, 33:599-602, 1976.

  18. FALLOON IRH, COVERDALE JH, BROKER C: Psychosocial interventions in schizophrenia: A review. Int J Ment Health, 25:3-21, 1996.

  19. GILBERT PL, HARRIS J, McADAMS LA, JESTE DV: Neuroleptic withdrawal in schizophrenia patients: a review of the literature. Archives General Psychiatry, 52:173-188, 1995.

  20. GUNDERSON JG, FRANK A, KATZ HM, VANICELLI ML, FROSCH JP: Effects of psychotherapy in schizophrenia. Schizophrenia Bull, 10:564-98, 1984.

  21. HARVARD MEDICAL SCHOOL: The Harvard Mental Health Letter. The psychosocial treatment of schizophrenia- Part I, 18(2): 1-4, 2001.

  22. HAUG HJ, WIRZ-JUSTICE A, ROSSLER W: Actigraphy to measure day structure as a therapeutic variable in the treatment of schizophrenic patients. Acta Psychiatr Scand, 102(Supl. 407):91-5, 2000.

  23. HERZ MI: Early interventions in schizophrenia. En: Psychosocial Treatment of Schizophrenia. Herz MI, Keith SJ, Docherty JP (Edit.). Elsevier Science Publishers. Amsterdam, Vol.4:25-44, 1990.

  24. HOGARTY GE: Prevention of relapse in chronic schizophrenic patients. J Clin Psychiatry, 54:18-23, 1993.

  25. HUMMER OM, FLEISCHACKER WW: Compliance with antipsychotic treatment. Acta Psychiatrica Scandinavica, 102(Supl 407):83-86, 2000.

  26. HUXLEY N, RENDALL M, SEDERER LL: Psychosocial treatments in schizophrenia. A review of the past 20 years. J Nervous Mental Disease, 188:187-201, 2000.

  27. JONHSON DAW: Depot neuroleptics. En: Antipsychotic Drugs and Their Side Effects. Barnes TRF (ed.). London Academy Press; Londres,205-212,1993.

  28. KANE JM: Management Issues in Schizophrenia. Martín Dunitz Ltd. Londres, 2000.

  29. KAY S, FIZBEN A, OPLER L: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bull, 13:261-76, 1987.

  30. KISSLING W: Compliance, quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiatrica, 89(supl 382):16-24, 1994.

  31. LEHMAN: Commentary: What happens to pychosocial treatment on the way to the clinic. Schizophrenia Bull, 26(1):137-44, 2000.

  32. LIBERMAN RP: Biobehavioral therapy: Interactions between pharmacotherapy and behavior therapy in schizophrenia. En: Outcome and Innovation in Psychological Treatment of Schizophrenia. Wykes T, Tarrier N, Lewis S (eds.). Edit.Wiley, Chichester, 179-199, 1998.

  33. LIBERMAN RP: Psychosocial treatment for schizophrenia. Psychiatry, 57:104-14, 1994.

  34. LINDEN M, GODERMAN F, GAEBEL W, KOPKE W: A prospective study of factors influencing adherence to a continuos neuroleptic treatment program in schizophrenia patients during 2 years. Schizophrenia Bull, 27(4):585-596, 2001.

  35. LUBORSKY L, SINGER B, LUBORSKY L: Comparative studies of psychotherapies: is it true that “everybody has won and all must have prizes?”, en Evaluation of Psychological Therapies, and their Interaction. Ed. Spitzer RL, Klein DF (eds.). Johns Hopkins Univ Press, Baltimore, 3-22, 1976.

  36. MARDER SR: Integrating pharmacological and psychosocial treatments for schizophrenia. Acta Psychiatr Scan, 407:87-90, 2000.

  37. MARI JJ, STEINER D: An overview of family interventions and relapse on schizophrenia: meta-analysis of research findings. Psychological Medicine, 24:565-78, 1994.

  38. Mc EVOY J: The expert consensus guideline series: treatment of schizophrenia. J Clinical Psychiatry, 60(Supl): 11, 1999.

  39. Mc PHILLIPS M, SENSKY T: Coercion, adherence or collaboration? Influences on compliance with medication. En: Outcome an Innovation in Psychological Treatment of Schizophrenia. Edit Wykes T, Tarrier N, Lewis S (eds.). Wiley and Sons, Londres, 161-177, 1998

  40. MELTZER HY: Outcome in schizophrenia: Beyond symptom reduction. J Clin Psychiatry, 60:3-7, 1999.

  41. MOJTABAI R, NICHOLSON R, CARPENTER B: Role of psychosocial treatments in the management of schizophrenia: A meta-analytic review of controlled outcome studies. Schizophrenia Bull, 24:569-87, 1998.

  42. MUNK-JORGENSEN P: Abstract book 13th International symposium for the psychological treatment of schizophrenia and other psychoses. Acta Psychiatrica Scandinavica, 404(102):1-81, 2000.

  43. ORGANIZACION MUNDIAL DE LA SALUD: CIE 10. Trastornos Mentales y del Comportamiento. Descripción Clínica y Pautas para el Diagnóstico. OMS, España; 1992.

  44. ORTEGA H, VALENCIA M: El tratamiento farmacológico de la esquizofrenia. En: Esquizofrenia: Estado actual y Perspectivas. Ortega H, Valencia M (ed.) Colección de libros del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, 349- 398, México, 2001.

  45. PENN DL, MUESER KT: Research update on the psychosocial treatment of schizophrenia. Am J Psychiatry, 153:607-17, 1996.

  46. PERKINS D: Adherence to antipsychotic medications. J Clin Psychiatry, 60:25-30, 1999.

  47. PERKINS D: Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry, 63:1121-1128, 2002.

  48. QUALITY ASSURANCE PROJECT: Treatment outlines for the management of schizofrenia. Australian New Zeland J Psychiatry, 18:19-38, 1984.

  49. ROBINS LN: The composite International Diagnostic Interview. Arch Gen Psychiatry, 45:1069-1077, 1990.

  50. ROSSLER W, HAUG HJ, MUNK-JORGENSEN P:. The psycosocial basis of schizophrenia. Acta Psychiatrica Scandinavica, 407 (102):1-99, 2000.

  51. SCHWARTZ BJ, CECIL A, IQBAL N: Psychosocial treatments of schizophrenia. Psychiatric Annals, 23:216-21, 1993.

  52. SMITH ML, GLASS GV, MILLER TI: The benefits of psychotherapy. Johns Hopkins University Press, Baltimore, 1980.

  53. TARRIER N, HADDOCK G, BARROWCLOUGH: Training and dissemination: research to practice in innovative psychosocial treatments for schizophrenia. En: Outcome and Innovation in Psychological Treatment of Schizophrenia. Wykes T, Tarrier N, Lewis S (eds.). Wiley, 215-236, Chichester, 1998.

  54. VALENCIA M, OTERO BR, RASCON ML: Un modelo de intervención clínica en un hospital mental. Acta Psiquiátrica Psicológica América Latina, 32:41-51, 1986.

  55. VALENCIA M: El hospital mental como instrumento terapéutico: El rol del psicólogo en la práctica clínica institucional. Rev Mexicana Psicología, 8:99-107, 1991.

  56. VALENCIA M: El tratamiento psicosocial en los pacientes con esquizofrenia. En: Esquizofrenia: Estado Actual y Perspectivas. Ortega H, Valencia M (eds.). Colección de libros del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, 399-454, México, 2001.

  57. VALENCIA M: Formulación de principios de tratamiento y rehabilitación del paciente psicótico. Rev Mexicana Psicologia, 3:37-43, 1986.

  58. VALENCIA M: Manejo psicosocial del paciente esquizofrénico. Rev Psiquiatria, 12:72-86, 1996.

  59. VALENCIA M. OTERO BR, RASCON ML: Un modelo de intervención clínica en un hospital mental. Acta Psiquiatr Psicol Am Latina, 32:41-51, 1986.

  60. VALENCIA M: Programa de intervención psicosocial para pacientes esquizofrénicos crónicos. Salud Mental, 22 (número especial):128-137, 1999.

  61. VALENCIA M, ROJAS E, GONZALEZ C, RAMOS L, VILLATORO J: Evaluación del funcionamiento psicosocial en pacientes de un centro de salud. Rev Salud Pública México, 31:674-87, 1989.

  62. VALENCIA M: Tratamiento psicosocial en pacientes esquizofrénicos del Instituto Mexicano de Psiquiatría. Salud Mental, 2:31-40, 1999.

  63. VALENCIA M: Un programa de tratamiento psicosocial para pacientes psicóticos agudos. Rev Psiquiatría, 12:72-86, 1988.

  64. VALENCIA M, RASCON ML: Abordaje psicoterapéutico de la esquizofrenia en pacientes agudos y crónicos. Revista Iberoamericana Psicologia, 8(4):18-33, 1998.

  65. VALENCIA M, ORTEGA H, RASCON ML, GOMEZ L: Evaluación de la combinación de los tratamientos psicosocial y farmacológico en pacientes con esquizofrenia. Actas Españolas Psiquiatria, 30 (6):358-369, 2002.

  66. VALENCIA M, LARA MC, RASCON ML, ORTEGA H: La importancia de los tratamientos farmacológico y psicosocial de los pacientes con esquizofrenia. Revista Latinoamericana Psiquiatria, 2(1):6-21, 2002.

  67. WALLACE CJ, LIBERMAN RP, TAUBER R, WALLACE J: The independent living skills survey: A comprehensive measure of the community functioning of severely and persistently mentally ill individuals. Schizophrenia Bull, 26:631-658, 2000.

  68. WEIDEN P, RAPKIN B, MOTT T, ZYGMUNT A, GOLDMAN D y cols.: Rating of medication influences (ROMI) scale in schizophrenia. Schizophrenia Bulletin, 20(2):297-310, 1994.

  69. WYKES T, TARRIER N, LEWIS S: Outcome and Innovation in Psychological Treatment of Schizophrenia. Wiley & Sons. Chichester, 1998.

  70. YOUNG JL, ZONANA HV, SHEPLER L: Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law, 14:105-122, 1986.




2020     |     www.medigraphic.com